Evidence map›Paper›PMID 34713168›Full record

ArticleFrontiers in digital health2021

Machine Learning-Based Extraction of Breast Cancer Receptor Status From Bilingual Free-Text Pathology Reports.

Antoine Pironet, Hélène A Poirel, Tim Tambuyzer, Harlinde De Schutter, Lien van Walle, Joris Mattheijssens, Kris Henau, Liesbet Van Eycken, Nancy Van Damme

Abstract read
In one paragraph

Article in Frontiers in digital health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antoine PironetBelgian Cancer Registry, Brussels, Belgium.
Hélène A PoirelBelgian Cancer Registry, Brussels, Belgium.
Tim TambuyzerBelgian Cancer Registry, Brussels, Belgium.
Harlinde De SchutterBelgian Cancer Registry, Brussels, Belgium.
Lien van WalleBelgian Cancer Registry, Brussels, Belgium.
Joris MattheijssensBelgian Cancer Registry, Brussels, Belgium.
Kris HenauBelgian Cancer Registry, Brussels, Belgium.
Liesbet Van EyckenBelgian Cancer Registry, Brussels, Belgium.
Nancy Van DammeBelgian Cancer Registry, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As part of its core business of gathering population-based information on new cancer diagnoses, the Belgian Cancer Registry receives free-text pathology reports, describing results of (pre-)malignant specimens. These reports are provided by 82 laboratories and written in 2 national languages, Dutch or French. For breast cancer, the reports characterize the status of estrogen receptor, progesterone receptor, and Erb-b2 receptor tyrosine kinase 2. These biomarkers are related with tumor growth and prognosis and are essential to define therapeutic management. The availability of population-scale information about their status in breast cancer patients can therefore be considered crucial to enrich real-world scientific studies and to guide public health policies regarding personalized medicine. The main objective of this study is to expand the data available at the Belgian Cancer Registry by automatically extracting the status of these biomarkers from the pathology reports. Various types of numeric features are computed from over 1,300 manually annotated reports linked to breast tumors diagnosed in 2014. A range of popular machine learning classifiers, such as support vector machines, random forests and logistic regressions, are trained on this data and compared using their

Indexed as

breast cancermachine learningnatural language processingpathologyreceptor status

Identifiers

PMID34713168
PMCPMC8522027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.